You are here:Home-Chemical Inhibitors & Agonists-Epigenetics-MicroRNA-MIR17PTi
MIR17PTi

Chemical Structure : MIR17PTi

CAS No.:

MIR17PTi

Catalog No.: PC-35397Not For Human Use, Lab Use Only.

MIR17PTi is a novel LNA gapmeR antisense oligonucleotide (LNA-ASO), first-in-class inhibitor of pri-mir-17-92.

Packing Price Stock Quantity

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

    Biological Activity

    MIR17PTi is a novel LNA gapmeR antisense oligonucleotide (LNA-ASO), first-in-class inhibitor of pri-mir-17-92; impairs the proliferation of several cancer cell lines established from both solid and hematologic tumors by on-target antisense activity, and more effectively as compared to miR-17-92s inhibitors; triggers apoptosis via impairment of homeostatic MYC/miR-17-92 feed-forward loops (FFLs) in patient-derived MM cells, induces MYC-dependent synthetic lethality; exerts strong in vivo anti-tumor activity in NOD-SCID mice bearing clinically relevant models of MM.

    Physicochemical Properties

    M.Wt
    Formula
    Appearance Solid
    CAS No.
    Storage
    Solide Powder
    -20 °C 12 Months; 4°C 6 Months
    In Solvent
    -80 °C 6 Months; -20°C 6 Months
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    5'-TACTTGCTTGGCTT-3'

    References

    1. Morelli E, et al. Blood. 2018 Jul 11. pii: blood-2018-03-836601.

    Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    Contact Us sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    Get Quote

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • Additional Information: